| Trial ID: | L2083 |
| Source ID: | NCT00701831
|
| Associated Drug: |
Insulin Glargine
|
| Title: |
Assessment of Insulin Glargine in Type 2 Patients for Good Glycemic Control
|
| Acronym: |
LANTIT
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Insulin glargine
|
| Outcome Measures: |
Primary: HbA1c, FBG, after treatment end (6 months)|Final dose, after treatment end (6 months)|Number of dose adjustment, after treatment end (6 months)|Time to dose titration, after treatment end (6 months) | Secondary: Hypoglycemia, after treatment end (6 months)|Noctural hypoglycemia, after treatment end (6 months)|DTSQ, after treatment end (6 months)|Physician Satisfaction Questionnaire, after treatment end (6 months)
|
| Sponsor/Collaborators: |
Sponsor: Sanofi
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
241
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2008-05
|
| Completion Date: |
2010-10
|
| Results First Posted: |
|
| Last Update Posted: |
2010-11-04
|
| Locations: |
Sanofi-Aventis Administrative Office, Istanbul, Turkey
|
| URL: |
https://clinicaltrials.gov/show/NCT00701831
|
